Retrophin Inc (NASDAQ:RTRX) was up 8% on Thursday . The company traded as high as $27.81 and last traded at $27.70. Approximately 607,420 shares traded hands during trading, an increase of 80% from the average daily volume of 337,893 shares. The stock had previously closed at $25.66.
A number of equities research analysts have recently weighed in on RTRX shares. Zacks Investment Research raised shares of Retrophin from a “sell” rating to a “hold” rating in a report on Thursday, September 27th. Canaccord Genuity started coverage on shares of Retrophin in a report on Friday, August 17th. They set a “buy” rating on the stock. BidaskClub lowered shares of Retrophin from a “buy” rating to a “hold” rating in a report on Friday, July 27th. Finally, Jefferies Financial Group began coverage on shares of Retrophin in a report on Tuesday. They set a “buy” rating and a $44.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $43.50.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.39). Retrophin had a negative net margin of 69.38% and a negative return on equity of 36.20%. The business had revenue of $40.70 million during the quarter, compared to analysts’ expectations of $44.36 million. During the same period in the previous year, the company posted $0.15 earnings per share. Retrophin’s revenue for the quarter was up 1.0% compared to the same quarter last year. Sell-side analysts forecast that Retrophin Inc will post -2.12 earnings per share for the current year.
In other Retrophin news, CEO Steve Aselage sold 12,000 shares of the company’s stock in a transaction on Friday, August 31st. The shares were sold at an average price of $32.00, for a total value of $384,000.00. Following the sale, the chief executive officer now directly owns 257,883 shares of the company’s stock, valued at $8,252,256. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.67% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of RTRX. Meeder Asset Management Inc. boosted its holdings in Retrophin by 315.6% in the third quarter. Meeder Asset Management Inc. now owns 4,663 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 3,541 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Retrophin in the second quarter valued at $136,000. Sei Investments Co. purchased a new stake in shares of Retrophin during the 2nd quarter worth about $141,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Retrophin during the 1st quarter worth about $206,000. Finally, Hartford Investment Management Co. purchased a new stake in shares of Retrophin during the 2nd quarter worth about $216,000.
Retrophin Company Profile (NASDAQ:RTRX)
Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Further Reading: Fundamental Analysis
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.